e-learning
resources
London 2016
Monday, 05.09.2016
IPF treatment I
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Twenty-four week decline in forced vital capacity predicts mortality at week 52 in the INPULSIS® trials
Luca Richeldi (Southampton, United Kingdom), Luca Richeldi, Arata Azuma, Moisés Selman, Wenbo Tang, Jorge Capapey, Susanne Stowasser, Vincent Cottin
Source:
International Congress 2016 – IPF treatment I
Session:
IPF treatment I
Session type:
Oral Presentation
Number:
1814
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Luca Richeldi (Southampton, United Kingdom), Luca Richeldi, Arata Azuma, Moisés Selman, Wenbo Tang, Jorge Capapey, Susanne Stowasser, Vincent Cottin. Twenty-four week decline in forced vital capacity predicts mortality at week 52 in the INPULSIS® trials. Eur Respir J 2016; 48: Suppl. 60, 1814
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Real World experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in IPF
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Effect of baseline FVC on lung function decline with nintedanib in patients with IPF
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies
Source: International Congress 2016 – New and old therapies for chronic lung diseases
Year: 2016
Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Effect of anti-acid medication on reduction in FVC decline with nintedanib
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Challenges in idiopathic pulmonary fibrosis trials: the point on end-points
Source: Eur Respir Rev 2011; 20: 195-200
Year: 2011
The clinical significance of 24hr continuous monitoring of SpO2 during daily life in the patients with interstitial pneumonia
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP
Source: International Congress 2016 – IPF treatment I
Year: 2016
Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Source: International Congress 2016 – IPF treatment I
Year: 2016
A six minute walking test (6MWT) derived index (O2-GAP) predicts mortality in IPF
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Source: Eur Respir Rev 2012; 21: 161-167
Year: 2012
Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Severe pulmonary hypertension in patients with emphysema but preserved FEV1: Prognosis and response to treatment
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF treatment II
Year: 2016
A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer
Source: Eur Respir J 2013; 41: 262-269
Year: 2013
Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study
Source: Annual Congress 2013 –Pulmonary circulation: treatment
Year: 2013
Effect of an 8 week pulmonary rehabilitation program in patients with interstitial lung diseases in India.
Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)?
Year: 2018
Effect of baseline composite physiologic index on benefit of nintedanib in IPF
Source: International Congress 2016 – IPF treatment I
Year: 2016
Idiopathic pulmonary fibrosis: Gender differences in survival and functional decline. A retrospective study
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept